Nemifitide: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides →
📌TL;DR
- •1 community protocols documented
- •Evidence level: Anecdotal Reports
- •Based on 5 community reports
- •Stacking patterns detailed below
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Availability | Nemifitide was studied in 12 clinical trials with over 430 subjects. Phase 2 and phase 3 studies used subcutaneous injection at doses ranging from 0.2 mg/kg to fixed 18 mg daily for 5-14 days. | Nemifitide is essentially unavailable to the general community. It has not been approved for marketing and is not sold by research peptide vendors. Virtually no community experimentation exists. | high Unlike most peptides on this site, nemifitide has meaningful clinical trial data but virtually no community usage due to complete unavailability outside of clinical trials. |
| Target Population | Clinical trials enrolled patients with diagnosed major depressive disorder. The rapid-onset antidepressant effects (5-7 days) were evaluated using standard depression rating scales. | Any community interest is theoretical, driven by the novel mechanism (5-HT2A modulation) and rapid onset of action compared to conventional antidepressants. | high Self-treatment of depression with investigational compounds is particularly risky. Nemifitide's clinical data is specifically for supervised medical treatment of diagnosed MDD. |
Compare these community approaches with published research findings.
Community Protocols
Clinical Trial-Based Protocol
Niche- Route
- Subcutaneous
- Dose
- 0.2 mg/kg (approximately 14-18 mg for most adults)
- Frequency
- Once daily
- Duration
- 5-14 days
Directly adapted from phase 2 clinical trial protocols; very few community users have attempted this
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 5+ self-experimenters report. Free with email.
150+ peptide profiles · 30+ comparisons · 18 research tools
Sources
- Reddit r/Nootropics|Nemifitide/INN-00835 discussions (limited, primarily mechanism-focused)(accessed 2026-02-16)
- Wikipedia|Nemifitide article with clinical trial summary(accessed 2026-02-16)
- PubMed|Clinical pharmacokinetic studies with INN 00835 (nemifitide)(accessed 2026-02-16)
Community Evidence Overview#
This page presents information about Nemifitide (INN-00835) in the context of community peptide use. This is not clinical evidence and should not be used as medical guidance.
Unlike most peptides covered on this site, Nemifitide has virtually no community usage. It has not been approved for marketing, is not sold by research peptide vendors, and has essentially zero self-experimenter reports. This page exists primarily to provide context about the compound's clinical development for those who encounter references to it in nootropic or peptide discussions.
Clinical Context#
Nemifitide has more clinical trial data than many community-used peptides, with over 430 subjects across 12 clinical trials. Phase 2 studies demonstrated rapid-onset antidepressant effects (within 5-7 days) at doses of 0.2 mg/kg subcutaneously. A favorable safety profile was observed across all trials. However, the compound has not received regulatory approval and remains investigational.
Why No Community Adoption#
Several factors explain the absence of community experimentation with nemifitide:
- Unavailability: The compound is not synthesized or sold by research peptide vendors
- Route requirement: Subcutaneous injection is required (no oral activity), creating a barrier for casual use
- Depression indication: The primary use case (MDD treatment) involves serious psychiatric illness that is risky to self-treat
- Lack of nootropic appeal: Unlike some antidepressant-related compounds, nemifitide's mechanism does not have obvious nootropic applications that would attract the cognitive enhancement community
Important Caveats#
- Self-treatment of depression with investigational compounds carries serious risks
- Nemifitide is not available from commercial sources
- All clinical data is from supervised medical settings
- The compound has not received regulatory approval despite reaching phase 3
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Nemifitide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.